Literature DB >> 12065233

SALL1 expression in the human pituitary-adrenal/gonadal axis.

Y Ma1, L Chai, S C Cortez, E G Stopa, M M Steinhoff, D Ford, J Morgan, A L Maizel.   

Abstract

SALL1 was originally identified on the basis of its DNA sequence homology to the region-specific homeotic gene Sal, in Drosophila melanogaster, which acts as a downstream target of hedgehog/tumor growth factor-beta-like decapentaplegic signals. The SALL1 gene has been associated with the Townes-Brocks Syndrome (TBS), a disorder characterized by multiorgan dysgenesis including renal and genital malformations. In this study, SALL1 message production was evaluated in association with the tissue localization of the protein product of SALL1, p140. SALL1 protein expression was observed in various adult and fetal tissues which elaborate reproductive endocrine hormones. The p140 was localized in specific microanatomic sites of the pituitary, adrenal cortex and the placenta. In the human pituitary, SALL1 protein expression was limited to the adenohypophysis, where it colocalized to those cells producing GH and the gonadotropins, LH and FSH. SALL1 expression was also found in most of the fetal and adult adrenal cortex in addition to the trophoblastic cells of the placenta. This pattern of expression complements prior studies demonstrating p140 in testicular fetal Leydig cells, adult Leydig and Sertoli cells, and granulosa cells of the ovary. The SALL1 protein was also shown here to be highly expressed in trophoblast tumors, which overproduce sex hormones. The expression patterns of SALL1 at multiple levels of the reproductive endocrine axis and the phenotypic effects associated with TBS suggest that SALL1 may have an important role in the interaction of the pituitary-adrenal/gonadal axis during reproduction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065233     DOI: 10.1677/joe.0.1730437

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  8 in total

Review 1.  Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit.

Authors:  Hitoshi Ishimoto; Robert B Jaffe
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

Review 2.  The role of stem cell factor SALL4 in leukemogenesis.

Authors:  Chong Gao; Nikki R Kong; Li Chai
Journal:  Crit Rev Oncog       Date:  2011

3.  SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.

Authors:  Yupo Ma; Wei Cui; Jianchang Yang; Jun Qu; Chunhui Di; Hesham M Amin; Raymond Lai; Jerome Ritz; Diane S Krause; Li Chai
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

4.  Genome-Wide Analysis and Function Prediction of Long Noncoding RNAs in Sheep Pituitary Gland Associated with Sexual Maturation.

Authors:  Hua Yang; Jianyu Ma; Zhibo Wang; Xiaolei Yao; Jie Zhao; Xinyue Zhao; Feng Wang; Yanli Zhang
Journal:  Genes (Basel)       Date:  2020-03-17       Impact factor: 4.096

5.  Endocrine abnormalities in Townes-Brocks syndrome.

Authors:  Cara Lawrence; Irene Hong-McAtee; Bryan Hall; James Hartsfield; Andrew Rutherford; Tracy Bonilla; Carolyn Bay
Journal:  Am J Med Genet A       Date:  2013-07-25       Impact factor: 2.802

6.  High expression of KIF26B in breast cancer associates with poor prognosis.

Authors:  Qun Wang; Zong-Bin Zhao; Geng Wang; Zhen Hui; Ming-Hua Wang; Jun-Feng Pan; Hong Zheng
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

7.  Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex.

Authors:  Jiayun Lu; Ha-Won Jeong; Hawon Jeong; Nikki Kong; Youyang Yang; John Carroll; Hongbo R Luo; Leslie E Silberstein; Li Chai
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

8.  Epigenetic modification of SALL1 as a novel biomarker for the prognosis of early stage head and neck cancer.

Authors:  Kiyoshi Misawa; Yuki Misawa; Atsushi Imai; Daiki Mochizuki; Shiori Endo; Masato Mima; Ryuji Ishikawa; Hideya Kawasaki; Takashi Yamatodani; Takeharu Kanazawa
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.